- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00474786
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib (INTORSECT)
28. oktober 2013 oppdatert av: Pfizer
A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
This is an international, randomized, open-label, outpatient, multicenter study.
Subjects will be assigned in a 1:1 ratio to 1 of 2 treatment arms: temsirolimus 25 mg once weekly by intravenous (IV) infusion or sorafenib 400 mg by mouth (PO) twice daily (BID).
These investigational drugs will be administered in 6-week cycles for the duration of the study, up to 24 months.
Subjects will be stratified by nephrectomy status, duration of response to sunitinib therapy, Memorial Sloan Kettering Cancer Center (MSKCC) prognostic group, and RCC tumor histology.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
512
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Buenos Aires, Argentina, C1437JCP
- Pfizer Investigational Site
-
Buenos Aires, Argentina, C1426ANZ
- Pfizer Investigational Site
-
Buenos Aires, Argentina, C1122AAL
- Pfizer Investigational Site
-
Nueva Cordoba, Argentina, X5006HBF
- Pfizer Investigational Site
-
Tucuman, Argentina, T4000 IAK
- Pfizer Investigational Site
-
-
Santa Fé
-
Rosario, Santa Fé, Argentina, S2000KZE
- Pfizer Investigational Site
-
-
-
-
New South Wales
-
Kogarah, New South Wales, Australia, 2217
- Pfizer Investigational Site
-
St Leonards, New South Wales, Australia, 2065
- Pfizer Investigational Site
-
Westmead, New South Wales, Australia, 2145
- Pfizer Investigational Site
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Pfizer Investigational Site
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Pfizer Investigational Site
-
Elizabeth Vale, South Australia, Australia, 5112
- Pfizer Investigational Site
-
Woodville South, South Australia, Australia, 5011
- Pfizer Investigational Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Pfizer Investigational Site
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 5L3
- Pfizer Investigational Site
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Pfizer Investigational Site
-
Victoria, British Columbia, Canada, V8R 6V5
- Pfizer Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- Pfizer Investigational Site
-
Halifax, Nova Scotia, Canada, B3H 3A7
- Pfizer Investigational Site
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Pfizer Investigational Site
-
-
Ontario
-
Cornwall, Ontario, Canada, K6R 5S5
- Pfizer Investigational Site
-
Hamilton, Ontario, Canada, L8N 4A6
- Pfizer Investigational Site
-
London, Ontario, Canada, N6A 4G5
- Pfizer Investigational Site
-
London, Ontario, Canada, N6A 4L6
- Pfizer Investigational Site
-
Ottawa, Ontario, Canada, K1H 8L6
- Pfizer Investigational Site
-
Ottawa, Ontario, Canada, K1Y 4K7
- Pfizer Investigational Site
-
Toronto, Ontario, Canada, M4N 3M5
- Pfizer Investigational Site
-
Toronto, Ontario, Canada, M5G 2M9
- Pfizer Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H3G 1A4
- Pfizer Investigational Site
-
-
-
-
Santiago
-
Providencia, Santiago, Chile
- Pfizer Investigational Site
-
-
-
-
-
Aarhus C, Danmark, 8000
- Pfizer Investigational Site
-
Herlev, Danmark, 2730
- Pfizer Investigational Site
-
-
-
-
-
Tampere, Finland, 33 521
- Pfizer Investigational Site
-
Turku, Finland, 20 520
- Pfizer Investigational Site
-
-
-
-
California
-
Duarte, California, Forente stater, 91010
- Pfizer Investigational Site
-
La Jolla, California, Forente stater, 92037
- Pfizer Investigational Site
-
La Jolla, California, Forente stater, 92093
- Pfizer Investigational Site
-
Los Angeles, California, Forente stater, 90095
- Pfizer Investigational Site
-
Los Angeles, California, Forente stater, 90095-6984
- Pfizer Investigational Site
-
Orange, California, Forente stater, 92868
- Pfizer Investigational Site
-
Riverside, California, Forente stater, 92505
- Pfizer Investigational Site
-
San Diego, California, Forente stater, 92103
- Pfizer Investigational Site
-
-
Connecticut
-
Meriden, Connecticut, Forente stater, 06451
- Pfizer Investigational Site
-
-
Indiana
-
Municie, Indiana, Forente stater, 47303
- Pfizer Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40202
- Pfizer Investigational Site
-
-
Louisiana
-
Metairie, Louisiana, Forente stater, 70006
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21201
- Pfizer Investigational Site
-
Bethesda, Maryland, Forente stater, 20817
- Pfizer Investigational Site
-
-
Mississippi
-
Tupelo, Mississippi, Forente stater, 38801
- Pfizer Investigational Site
-
-
New York
-
New York, New York, Forente stater, 10065
- Pfizer Investigational Site
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Pfizer Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73120
- Pfizer Investigational Site
-
Tulsa, Oklahoma, Forente stater, 74104
- Pfizer Investigational Site
-
-
Texas
-
Austin, Texas, Forente stater, 78731
- Pfizer Investigational Site
-
Dallas, Texas, Forente stater, 75246
- Pfizer Investigational Site
-
Dallas, Texas, Forente stater, 75226
- Pfizer Investigational Site
-
San Antonio, Texas, Forente stater, 78229
- Pfizer Investigational Site
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112-5550
- Pfizer Investigational Site
-
Salt Lake City, Utah, Forente stater, 84412
- Pfizer Investigational Site
-
-
Washington
-
Seattle, Washington, Forente stater, 98101
- Pfizer Investigational Site
-
-
-
-
-
Angers, Frankrike, 49100
- Pfizer Investigational Site
-
Besancon, Frankrike, 25000
- Pfizer Investigational Site
-
Bordeaux, Frankrike, 33075
- Pfizer Investigational Site
-
Caen Cedex 05, Frankrike, 14076
- Pfizer Investigational Site
-
Clermont-Ferrand Cedex 1, Frankrike, 63011
- Pfizer Investigational Site
-
Dijon, Frankrike, 21079
- Pfizer Investigational Site
-
Lille, Frankrike, 59000
- Pfizer Investigational Site
-
Lyon Cedex 08, Frankrike, 69373
- Pfizer Investigational Site
-
Marseille Cedex 9, Frankrike, 13273
- Pfizer Investigational Site
-
Paris Cedex 15, Frankrike, 75908
- Pfizer Investigational Site
-
Poitiers Cedex, Frankrike, 86021
- Pfizer Investigational Site
-
Saint Herlain/Nantes Cedex, Frankrike, 44805
- Pfizer Investigational Site
-
Strasbourg, Frankrike, 67091
- Pfizer Investigational Site
-
Vandoeuvre Les Nancy, Frankrike, 54511
- Pfizer Investigational Site
-
Villejuif Cedex, Frankrike, 94805
- Pfizer Investigational Site
-
-
Cedex 5
-
Montpellier, Cedex 5, Frankrike, 34298
- Pfizer Investigational Site
-
-
-
-
-
Chieti, Italia, 66013
- Pfizer Investigational Site
-
Firenze, Italia, 50134
- Pfizer Investigational Site
-
Napoli, Italia, 80131
- Pfizer Investigational Site
-
Pavia, Italia, 27100
- Pfizer Investigational Site
-
Roma, Italia, 00144
- Pfizer Investigational Site
-
Roma, Italia, 00152
- Pfizer Investigational Site
-
Roma, Italia, 0144
- Pfizer Investigational Site
-
-
-
-
-
Hong Kong, Kina
- Pfizer Investigational Site
-
-
-
-
-
Seoul, Korea, Republikken, 120-752
- Pfizer Investigational Site
-
Seoul, Korea, Republikken, 138-736
- Pfizer Investigational Site
-
Seoul, Korea, Republikken, 110-744
- Pfizer Investigational Site
-
Seoul, Korea, Republikken, 135-710
- Pfizer Investigational Site
-
-
-
-
-
Dordrecht, Nederland, 3318 AT
- Pfizer Investigational Site
-
Leeuwarden, Nederland, 8934 AD
- Pfizer Investigational Site
-
Zwolle, Nederland, 8025 AB
- Pfizer Investigational Site
-
-
-
-
-
Singapore, Singapore, 169610
- Pfizer Investigational Site
-
-
-
-
-
Barcelona, Spania, 08025
- Pfizer Investigational Site
-
Madrid, Spania, 28007
- Pfizer Investigational Site
-
Madrid, Spania, 28041
- Pfizer Investigational Site
-
Sevilla, Spania, 41013
- Pfizer Investigational Site
-
Valencia, Spania, 46010
- Pfizer Investigational Site
-
-
Asturias
-
Oviedo, Asturias, Spania, 33006
- Pfizer Investigational Site
-
-
Barcelona
-
Badalona, Barcelona, Spania, 08916
- Pfizer Investigational Site
-
Sabadell, Barcelona, Spania, 08208
- Pfizer Investigational Site
-
-
-
-
-
Birmingham, Storbritannia, B15 2TH
- Pfizer Investigational Site
-
London, Storbritannia, SE1 9RT
- Pfizer Investigational Site
-
Manchester, Storbritannia, M23 9LT
- Pfizer Investigational Site
-
Newcastle upon Tyne, Storbritannia, NE4 6BE
- Pfizer Investigational Site
-
-
Birmingham
-
Edgbaston, Birmingham, Storbritannia, B5 7UG
- Pfizer Investigational Site
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Storbritannia, CB2 0QQ
- Pfizer Investigational Site
-
-
Manchester
-
Withington, Manchester, Storbritannia, M20 4BX
- Pfizer Investigational Site
-
-
-
-
-
Basel, Sveits
- Pfizer Investigational Site
-
Bruderholz, Sveits
- Pfizer Investigational Site
-
Luzern, Sveits, 6000
- Pfizer Investigational Site
-
Rheinstrasse 26, Sveits
- Pfizer Investigational Site
-
-
BS
-
Basel, BS, Sveits, 4031
- Pfizer Investigational Site
-
-
Basel
-
Kleinriehenstrasse 30, Basel, Sveits
- Pfizer Investigational Site
-
-
GE
-
Geneva, GE, Sveits, 1221
- Pfizer Investigational Site
-
-
-
-
-
Göteborg, Sverige, SE-413 45
- Pfizer Investigational Site
-
Lund, Sverige, 221 85
- Pfizer Investigational Site
-
Malmo, Sverige, 205 02
- Pfizer Investigational Site
-
-
-
-
-
Berlin, Tyskland, 10117
- Pfizer Investigational Site
-
Dresden, Tyskland, 01307
- Pfizer Investigational Site
-
Heidelberg, Tyskland, 69120
- Pfizer Investigational Site
-
Kassel, Tyskland, 34125
- Pfizer Investigational Site
-
Luebeck, Tyskland, 23538
- Pfizer Investigational Site
-
Muenchen, Tyskland, 81675
- Pfizer Investigational Site
-
Neuss, Tyskland, 41464
- Pfizer Investigational Site
-
Ulm, Tyskland, 89081
- Pfizer Investigational Site
-
-
-
-
-
Budapest, Ungarn, H-1122
- Pfizer Investigational Site
-
-
-
-
-
Salzburg, Østerrike, 5020
- Pfizer Investigational Site
-
Wien, Østerrike, 1090
- Pfizer Investigational Site
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Histologically confirmed diagnosis of mRCC (regardless of histology or nephrectomy status) with well-documented Radiological PD by RECIST criteria or clinical PD as judged by the investigator while receiving first-line sunitinib therapy. Subjects must have at least 1 cycle of sunitinib therapy (minimum of four weeks continuously).
- At time of randomization, at least 2 weeks since prior treatment with sunitinib, palliative radiation therapy, and/or surgery.
At time of randomization, there must be at least 1 measurable lesion per RECIST. Lesions that have been previously irradiated or embolized cannot be selected as target lesions.
- More criteria apply
Exclusion Criteria:
- Metastatic CNS from RCC.
- Subjects who discontinued Sutent therapy due specifically to intolerance.
- Prior systemic therapy for mRCC other than sunitinib.
Active ketonuria, secondary to poorly controlled diabetes mellitus
- More criteria apply
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: 1
|
Subjects randomized to arm B will take sorafenib 400 mg (2 x 200 mg tablets) PO, BID (total daily dose of 800 mg).
|
|
Eksperimentell: 2
|
Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly.
This infusion is to be administered over a 30-60 minute period.
Subjects are to be pre-treated with 25-50 mg IV diphenhydramine (or comparable IV antihistamine) approximately 30 minutes before temsirolimus infusion.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-Free Survival (PFS)
Tidsramme: Baseline up to 24 Months
|
Interval from date of randomization until documentation of progressive disease (PD) by an independent tumor assessment according to Response Evaluation Criteria in Solid Tumor (RECIST) or death for any reason whichever occurred first.
|
Baseline up to 24 Months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression Free Survival (PFS) by Investigator Assessment
Tidsramme: Baseline up to 24 Months
|
Interval from date of randomization until documentation of PD by an investigator tumor assessment, symptomatic deterioration, or death for any reason whichever occurred first.
|
Baseline up to 24 Months
|
|
Percentage of Participants With Tumor Response
Tidsramme: Baseline up to 24 Months
|
Percentage of participants with tumor response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST and evaluated by independent central review.
CR/PR persisted on repeat imaging study at least 4 weeks after initial documentation of response.
PR had at least 30 percent decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.
|
Baseline up to 24 Months
|
|
Overall Survival (OS)
Tidsramme: Baseline to date of death from any cause (up to 24 months)
|
Overall survival was the duration from randomization to death.
For participants who are alive, overall survival was censored at the last contact.
|
Baseline to date of death from any cause (up to 24 months)
|
|
Percentage of Participants With PFS Events at 12, 24 and 36 Weeks by Independent Assessment
Tidsramme: Weeks 12, 24, and 36
|
PFS: Interval from date of randomization until documentation of PD by an independent tumor assessment according to RECIST or death for any reason whichever occurred first.
PFS calculated as (Weeks)=(randomization date minus first dose date plus 1) divided by 7.
|
Weeks 12, 24, and 36
|
|
Duration of Response (DR)
Tidsramme: Baseline up to 24 Months
|
Duration of response as defined by the time from CR or PR (whichever status recorded first) until the date of death or PD was objectively documented.
Median and its 95 percent confidence interval (95% CI) were estimated using Kaplan-Meier method.
|
Baseline up to 24 Months
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Baseline up to 24 months
|
Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose.
Relatedness to [study drug] was assessed by the investigator (Yes/No).
Participants with multiple occurrences of an AE within a category were counted once within the category.
|
Baseline up to 24 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.
- Grunwald V, Lin X, Kalanovic D, Simantov R. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Eur Urol. 2016 Dec;70(6):1006-1015. doi: 10.1016/j.eururo.2016.05.010. Epub 2016 May 26.
- Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014 Mar 10;32(8):760-7. doi: 10.1200/JCO.2013.50.3961. Epub 2013 Dec 2.
Hjelpsomme linker
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. september 2007
Primær fullføring (Faktiske)
1. januar 2012
Studiet fullført (Faktiske)
1. januar 2013
Datoer for studieregistrering
Først innsendt
15. mai 2007
Først innsendt som oppfylte QC-kriteriene
15. mai 2007
Først lagt ut (Anslag)
17. mai 2007
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
21. november 2013
Siste oppdatering sendt inn som oppfylte QC-kriteriene
28. oktober 2013
Sist bekreftet
1. oktober 2013
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter histologisk type
- Neoplasmer
- Urologiske neoplasmer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Nyresykdommer
- Urologiske sykdommer
- Adenokarsinom
- Neoplasmer, kjertel og epitel
- Nyre-neoplasmer
- Karsinom, nyrecelle
- Karsinom
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Enzymhemmere
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antibakterielle midler
- Proteinkinasehemmere
- Antibiotika, antineoplastisk
- Antifungale midler
- Sorafenib
- Sirolimus
Andre studie-ID-numre
- 3066K1-404
- B1771003
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .